Sector: MedicalProgenics Pharmaceuticals Inc. (NASDAQ: PGNX)
Headlines
- Progenics Announces Third Quarter 2009 Financial Results
Nov 09, 2009 08:00 AM | PGNX
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
Oct 29, 2009 09:30 AM | BMR, PGNX
- BioMed News Bytes: PGNX, SMTS, ZIOP, CXM, PSDV, BMTI
Oct 14, 2009 12:36 PM | AMD, BMTI, MDCO, PFS, PGNX, SMTS
- Progenics Regains Worldwide Rights to RELISTOR Franchise
Oct 14, 2009 07:00 AM | PGNX, WYE
- Progenics Announces Promotion of Mark R. Baker to President and Appoints Him to Board of Directors
Sep 16, 2009 07:00 AM | PGNX, WYE
- FDA Calendar Updates: MELA, PGNX, VPHM, WYE, NeurogesX, Thoratec
Aug 06, 2009 11:29 AM | MELA, NGSX, PGNX, THOR, VPHM, WYE
- FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX
Jun 08, 2009 06:35 PM | ARNA, DYAX, GSK, KERX, MITI, PGNX
- Top Picks For ASCO 2009
May 26, 2009 07:49 AM | ARIA, ARQL, BMY, CEPH, CRGN, EXEL
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study - May 29 2008 9:08AM
May 29, 2008 08:59 AM | PGNX, THRX, WYE
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study - Jun 1 2008 4:31AM
May 29, 2008 08:59 AM | PGNX, THRX, WYE
- CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results
Nov 09, 2009 09:52 AM | PGNX
- Progenics Announces Second Quarter 2009 Financial Results
Aug 06, 2009 08:05 AM | PGNX
- New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Aug 04, 2009 08:05 AM | PGNX, WYE
- Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
Jun 08, 2009 08:20 AM | PGNX, WYE
- Progenics Provides Update on Hepatitis C Program
Jun 08, 2009 08:18 AM | PGNX
- Progenics Announces First Quarter Financial Results
May 11, 2009 04:53 PM | PFE, PGNX, WYE
- Phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic, Non-Cancer Pain Patients
May 07, 2009 08:24 AM | PGNX, WYE
- Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update - Mar 16 2009 11:53AM
Mar 13, 2009 11:53 AM | PFE, PGNX, WYE
- Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update - Mar 13 2009 8:15AM
Mar 13, 2009 08:06 AM | PGNX
- Progenics Selects Subcutaneous Form of PRO 140, a Novel HIV Antibody Therapy, for Further Development
Feb 10, 2009 08:20 AM | PGNX
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 16 Filed by: MADDON PAUL J (10K)
Oct 19, 2009 12:39 PM
- Form 4 Olson William C For: Oct 01 (10K)
Oct 05, 2009 05:46 PM
- Form 4 ISRAEL ROBERT J For: Oct 01 (10K)
Oct 05, 2009 05:45 PM
- Form 4 Boyd Thomas A For: Oct 01 (10K)
Oct 05, 2009 05:44 PM
- Form 4 MCKINNEY ROBERT A For: Oct 01 (10K)
Oct 05, 2009 05:44 PM
- Form 4 Baker Mark Robert For: Oct 01 (10K)
Oct 05, 2009 05:43 PM
- Form 4 WILLIAMS NICOLE For: Jul 01 (10K)
Jul 06, 2009 04:37 PM
- Form 4 SCHEINBERG DAVID A For: Jul 01 (10K)
Jul 06, 2009 04:37 PM
- Form 4 GOFF STEPHEN P For: Jul 01 (10K)
Jul 06, 2009 04:37 PM
- Form 4 DALTON MARK F For: Jul 01 (10K)
Jul 06, 2009 04:33 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
PGNX
|
Compare to S&P
|
| YTD |
-60.52 %
|
-67.33 %
|
| 4 Weeks |
-8.74 %
|
-9.73 %
|
| 12 Weeks |
-23.78 %
|
-28.14 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 18.00 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: -0.91 %
|
|
Sales Growth in Last Quarter: -69.03 %
|
|
